Chronic Lymphocytic Leukemia
Conditions
Keywords
CLL, BTK, Bruton Tyrosine Kinase, acalabrutinib, ACP-196
Brief summary
This study is designed to evaluate the efficacy of acalabrutinib compared with rituximab in combination with idelalisib or bendamustine in previously treated subjects with chronic lymphocytic leukemia (CLL).
Interventions
Acalabrutinib monotherapy
DRUGRituximab
Rituximab in combination with idelalisib or bendamustine
DRUGIdelalisib
Idelalisib in combination with rituximab
DRUGBendamustine
Bendamustine in combination with rituximab
Sponsors
Acerta Pharma BV
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Men and women ≥ 18 years of age. 2. ECOG performance status of 0 to 2. 3. Diagnosis of CLL that meets published diagnostic criteria (Hallek 2008): 1. Monoclonal B-cells (either kappa or lambda light chain restricted) that are clonally co-expressing ≥ 1 B-cell marker (CD19, CD20, or CD23) and CD5. 2. Prolymphocytes may comprise ≤ 55% of blood lymphocytes. 3. Presence of ≥ 5 x 10\^9 B lymphocytes/L (5000/μL) in the peripheral blood (at any point since initial diagnosis). 4. Must have documented CD20-positive CLL. 5. Active disease meeting ≥ 1 of the following IWCLL 2008 criteria for requiring treatment: 1. Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia (hemoglobin \< 10 g/dL) and/or thrombocytopenia (platelets \< 100,000/μL). 2. Massive (i.e., ≥ 6 cm below the left costal margin), progressive, or symptomatic splenomegaly. 3. Massive nodes (i.e., ≥ 10 cm in the longest diameter), progressive, or symptomatic lymphadenopathy. 4. Progressive lymphocytosis with an increase of \> 50% over a 2-month period or a LDT of \< 6 months. LDT may be obtained by linear regression extrapolation of ALC obtained at intervals of 2 weeks over an observation period of 2 to 3 months. In subjects with initial blood lymphocyte counts of \< 30 x 10\^9/L (30,000/μL), LDT should not be used as a single parameter to define indication for treatment. In addition, factors contributing to lymphocytosis or lymphadenopathy other than CLL (e.g., infections) should be excluded. 5. Autoimmune anemia and/or thrombocytopenia that is poorly responsive to standard therapy. 6. Constitutional symptoms documented in the subject's chart with supportive objective measures, as appropriate, defined as ≥ 1 of the following disease-related symptoms or signs: i. Unintentional weight loss ≥ 10% within the previous 6 months before screening. ii. Significant fatigue (ECOG performance score 2; inability to work or perform usual activities). iii. Fevers higher than 100.5°F or 38.0°C for ≥ 2 weeks before screening without evidence of infection. iv. Night sweats for \> 1 month before screening without evidence of infection. 6. Meet the following laboratory parameters: 1. ANC ≥ 750 cells/μL (0.75 x 10\^9/L), or ≥ 500 cells/μL (0.50 x 10\^9/L) in subjects with documented bone marrow involvement, and independent of growth factor support 7 days before assessment. 2. Platelet count ≥ 50,000 cells/μL (50 x 10\^9/L), or ≥ 30,000 cells/μL (30 x 10\^9/L) in subjects with documented bone marrow involvement, and without transfusion support 7 days before assessment. Subjects with transfusion-dependent thrombocytopenia are excluded. If an Investigator has chosen bendamustine/rituximab as the Arm B treatment, platelets must be ≥ 75,000 cells/μL (75 x 10\^9/L). 3. Serum AST and ALT ≤ 2.0 x ULN. 4. Total bilirubin ≤ 1.5 x ULN. 5. Estimated creatinine clearance of ≥ 30 mL/min, calculated using the formula of Cockcroft and Gault \[(140-Age) • Mass (kg)/(72 • creatinine mg/dL); multiply by 0.85 if female\]. 7. Must have received ≥ 1 prior systemic therapies for CLL. Note: Single-agent steroids or localized radiation are not considered a prior line of therapy. If a single-agent anti-CD20 antibody was previously administered, subjects must have received ≥ 2 doses. 8. Women who are sexually active and can bear children must agree to use highly effective forms of contraception while on the study and for 2 days after the last dose of acalabrutinib, 90 days after the last dose of idelalisib, 6 months after the last dose of bendamustine, or 12 months after the last dose of rituximab, whichever is longer. Highly effective forms of contraception are defined in Section 9.2.5. 9. Men who are sexually active and can beget children must agree to use highly effective forms of contraception during the study and for 90 days after the last dose of idelalisib, 6 months after the last dose of bendamustine, or 12 months after the last dose of rituximab, whichever is longer. Highly effective forms of contraception are defined in Section 9.2.5. 10. Men must agree to refrain from sperm donation during the study and for 90 days after the last dose of idelalisib, 6 months after the last dose of bendamustine, or 12 months after the last dose of rituximab, whichever is longer. 11. Willing and able to participate in all required evaluations and procedures in this study protocol, including swallowing capsules without difficulty. 12. Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (in accordance with national and local patient privacy regulations).
Exclusion criteria
1. Known CNS lymphoma or leukemia. 2. Known prolymphocytic leukemia or history of, or currently suspected, Richter's syndrome. 3. Uncontrolled AIHA or ITP defined as declining hemoglobin or platelet count secondary to autoimmune destruction within the screening period or requirement for high doses of steroids (\> 20 mg daily of prednisone or equivalent). 4. Prior exposure to a BCL-2 inhibitor (e.g., venetoclax/ABT-199) or a BCR inhibitor (e.g., BTK inhibitors or PI3K inhibitors). Prior bendamustine is allowed if Investigator's choice for treatment in Arm B is idelalisib with rituximab. Bendamustine retreatment is allowed if the prior response to bendamustine lasted \> 24 months. 5. Received any chemotherapy, external beam radiation therapy, anticancer antibodies, or investigational drug within 30 days before first dose of study drug. 6. Corticosteroid use \> 20 mg daily prednisone equivalent within 1 week before first dose of study drug, except as indicated for other medical conditions such as inhaled steroid for asthma, topical steroid use, or as premedication for administration of study drug or contrast. For example, subjects requiring steroids at daily doses \> 20 mg prednisone equivalent systemic exposure daily, or those who are administered steroids for leukemia control or white blood cell count lowering are excluded. 7. Prior radio- or toxin-conjugated antibody therapy. 8. Prior allogeneic stem cell transplant or prior autologous transplant within 6 months of first dose of study drug(s) or presence of graft-vs-host disease or receiving treatment for graft-vs-host disease. 9. Major surgical procedure within 30 days of first dose of study drug. Note: If a subject had major surgery, they must have recovered adequately from any toxicity and/or complications from the intervention before the first dose of study drug. 10. History of prior malignancy except for the following: 1. Malignancy treated with curative intent and with no evidence of active disease present for more than 2 years before screening and felt to be at low risk for recurrence by treating physician. 2. Adequately treated lentigo maligna melanoma without current evidence of disease or adequately controlled nonmelanomatous skin cancer. 3. Adequately treated carcinoma in situ without current evidence of disease. 11. Significant cardiovascular disease such as uncontrolled or untreated symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification, or QTc \> 480 msec (calculated using Fridericia's formula: QT/RR\^0.33) at screening. Exception: Subjects with controlled, asymptomatic atrial fibrillation during screening are allowed to enroll on study. 12. Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach, or extensive small bowel resection that is likely to affect absorption, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass. 13. Received a live virus vaccination within 28 days of first dose of study drug. 14. Known history of infection with HIV or any uncontrolled active systemic infection (e.g., bacterial, viral, or fungal). For study sites in Germany: active infection with human immunodeficiency virus (seropositivity for HIV-1 or HIV-2 antibodies, and if positive, reactivity against the HIV-specific p24 antigen). 15. Active CMV infection (active viremia as evidenced by positive polymerase chain reaction \[PCR\] result for CMV DNA). 16. Serologic status reflecting active hepatitis B or C infection. 1. Subjects who are anti-HBc positive and who are surface antigen negative will need to have a negative PCR result before randomization. Those who are HbsAg-positive or hepatitis B PCR positive will be excluded. 2. Subjects who are hepatitis C antibody positive will need to have a negative PCR result before randomization. Those who are hepatitis C PCR positive will be excluded. 17. Ongoing, drug-induced liver injury, alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, ongoing extrahepatic obstruction caused by cholelithiasis, cirrhosis of the liver, or portal hypertension. 18. History of or ongoing drug-induced pneumonitis. 19. History of serious allergic reactions including anaphylaxis and toxic epidermal necrolysis. 20. History of stroke or intracranial hemorrhage within 6 months before first dose of study drug. 21. History of bleeding diathesis (e.g., hemophilia, von Willebrand disease). 22. Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists (e.g., phenprocoumon) within 7 days of first dose of study drug. 23. Presence of a gastrointestinal ulcer diagnosed by endoscopy within 3 months before screening. 24. Requires treatment with a strong CYP3A inhibitor/inducer. 25. Requires treatment with proton-pump inhibitors (e.g., omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole). Subjects receiving proton-pump inhibitors who switch to H2-receptor antagonists or antacids are eligible for enrollment to this study. 26. Breast feeding or pregnant. 27. Concurrent participation in another therapeutic clinical trial. 28. Prothrombin time/INR or aPTT (in the absence of a Lupus anticoagulant) \> 2.0 x ULN. Exception: Subjects receiving warfarin are excluded, however, those receiving other anticoagulant therapy who have a higher INR/aPTT may be permitted to enroll to this study after discussion with the medical monitor. 29. History of confirmed progressive multifocal leukoencephalopathy (PML)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival (PFS) Per Independent Review Committee (IRC) Assessment | IRC assessments from randomization date until disease progression or death or IRC discontinuation on 15Jan2019 (as IA per this data cutoff showed crossing superiority boundary) whichever came first, up to 22 months of follow-up | To evaluate the efficacy of acalabrutinib monotherapy (Arm A) compared with idelalisib/rituximab or bendamustine/rituximab (Arm B) based on Independent Review Committee (IRC) assessment of progression-free survival (PFS) per International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria (Hallek 2008) with incorporation of the clarification for treatment-related lymphocytosis (Cheson 2012) hereafter referred to as IWCLL 2008 criteria in subjects with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL). As planned and reported in the interim clinical study report (dated 17 July 2019), because the study did cross the boundary at interim analysis. IRC assessments were discontinued after the interim analysis. All IRC-related efficacy analyses in this clinical study report were based on the interim analysis data cutoff date of 15 January 2019. All other efficacy analyses were based on the final analysis data cutoff date of 03 September 2021. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival (PFS) Per Investigator Assessment | From randomization date to date of disease progression or death due to any cause or data cutoff date on 03Sep2021, whichever came first, regardless of use of subsequent anticancer therapy, until 53 months of follow-up. | PFS per investigator assessment based on the final analysis data cutoff date of 03 September 2021. |
| IRC-assessed Overall Response Rate (ORR) Per IWCLL 2008 Criteria Based on Data Cutoff 15 January 2019 From Interim Analysis | IRC assessments from randomization date until disease progression or death or IRC discontinuation on 15Jan2019 (as IA per this data cutoff showed crossing superiority boundary) whichever came first, up to 22 months of follow-up | IRC-assessed overall response rate (ORR) including complete response (CR), CR with incomplete blood count recovery (CRi) nodular PR (nPR), and Partial Response (PR) |
| Investigator Assessed Overall Response Rate (ORR) Per IWCLL 2008 Criteria Based on Data Cutoff 03 September 2021 | Investigator assessments were done from randomization date until date of death or date of exit from study or data cut off date on 03Sep2021, whichever came first, up to 53 months of follow-up. | IRC-assessed overall response rate (ORR) including complete response (CR), CR with incomplete blood count recovery (CRi) nodular PR (nPR), and Partial Response (PR) |
| Overall Survival (OS) | From randomization date to date of death due to any cause, or date of study discontinuation, or date of data cutoff on 03Sep2021, whichever came first until 54 months of follow-up. | Overall Survival (OS) was based on data cutoff date of 03Sep2021 |
| Duration of Response (DOR) Per Independent Review Committee (IRC) Assessment Based on 15 January 2019 Data Cutoff From Interim Analysis. | IRC assessments from randomization date until disease progression or death or IRC discontinuation on 15Jan2019 (as IA per this data cutoff showed crossing superiority boundary) whichever came first, up to 22 months of follow-up | Duration of Response (DOR) is defined as from the first documentation of CR, CRi, PR, or nPR to the earlier of the first documentation of disease progression or death from any cause. |
| Duration of Response (DOR) Per Investigator Assessment Based on 03 September 2021 Data Cutoff | Investigator assessments were done from randomization date until date of death or study discontinuation or data cutoff date on 03Sep2021, whichever came first up to 53 months of follow-up. | Duration of Response (DOR) is defined as from the first documentation of CR, CRi, PR, or nPR to the earlier of the first documentation of disease progression or death from any cause. |
| Time to Next Treatment (TTNT) Based on 03 September 2021 Data Cutoff | From randomization date to start of non-protocol specified subsequent anticancer therapy for CLL or death due to any cause or study discontinuation or data cutoff date on 03Sep2021,, whichever came first up to 53 months of follow-up. | Time to Next Treatment (TTNT) is defined as the time from date of randomization to date of institution of non-protocol-specified treatment for CLL (or first dose date of acalabrutinib for Arm B subjects crossing over to receive acalabrutinib) or death due to any cause, whichever comes first. |
Countries
Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Czechia, France, Germany, Hong Kong, Hungary, Israel, Italy, New Zealand, Poland, Russia, Singapore, Slovakia, South Korea, Spain, Sweden, Taiwan, Ukraine, United Kingdom, United States
Contacts
STUDY_DIRECTORAcerta Clinical Trials
1-888-292-9613; acertamc@dlss.com
Participant flow
Recruitment details
A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator's Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia. A total of 310 subjects met the eligibility criteria and were randomized to the acalabrutinib arm (N = 155) and IR/BR arm (N = 155). All but 3 subjects (1 randomized to acalabrutinib and 2 randomized to IR/BR) received study treatment.
Pre-assignment details
310 patients were enrolled in this study and agreed to move forward in participating in the trial.
Participants by arm
| Arm | Count |
|---|---|
| Arm A- Acala. 100 mg BID Arm A- Acalabrutinib 100 mg BID | 155 |
| Arm B: Investigator Choice (IR or BR)-Main Study Period IR or BR data not presented separately similar to combined treatment arms approved for D8223C00009 | 155 |
| Total | 310 |
Baseline characteristics
| Characteristic | Arm A- Acala. 100 mg BID | Total | Arm B: Investigator Choice (IR or BR)-Main Study Period |
|---|---|---|---|
| Age, Customized Age >=65 years | 97 Participants | 195 Participants | 98 Participants |
| Age, Customized Age < 65 Years | 58 Participants | 115 Participants | 57 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 2 Participants | 8 Participants | 6 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 147 Participants | 276 Participants | 129 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 6 Participants | 26 Participants | 20 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 7 Participants | 14 Participants | 7 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 3 Participants | 9 Participants | 6 Participants |
| Race (NIH/OMB) White | 145 Participants | 286 Participants | 141 Participants |
| Region of Enrollment Australia | 6 Participants | 12 Participants | 6 Participants |
| Region of Enrollment Europe | 131 Participants | 263 Participants | 132 Participants |
| Region of Enrollment Hong Kong | 0 Participants | 1 Participants | 1 Participants |
| Region of Enrollment Korea, Republic Of | 3 Participants | 7 Participants | 4 Participants |
| Region of Enrollment New Zealand | 3 Participants | 4 Participants | 1 Participants |
| Region of Enrollment North America | 8 Participants | 17 Participants | 9 Participants |
| Region of Enrollment Singapore | 3 Participants | 5 Participants | 2 Participants |
| Region of Enrollment Taiwan, Province Of China | 1 Participants | 1 Participants | 0 Participants |
| Sex: Female, Male Female | 47 Participants | 102 Participants | 55 Participants |
| Sex: Female, Male Male | 108 Participants | 208 Participants | 100 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 41 / 155 | 33 / 155 | 20 / 80 |
| other Total, other adverse events | 149 / 154 | 145 / 153 | 73 / 80 |
| serious Total, serious adverse events | 70 / 154 | 86 / 153 | 31 / 80 |
Outcome results
Primary
Progression-free Survival (PFS) Per Independent Review Committee (IRC) Assessment
To evaluate the efficacy of acalabrutinib monotherapy (Arm A) compared with idelalisib/rituximab or bendamustine/rituximab (Arm B) based on Independent Review Committee (IRC) assessment of progression-free survival (PFS) per International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria (Hallek 2008) with incorporation of the clarification for treatment-related lymphocytosis (Cheson 2012) hereafter referred to as IWCLL 2008 criteria in subjects with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL). As planned and reported in the interim clinical study report (dated 17 July 2019), because the study did cross the boundary at interim analysis. IRC assessments were discontinued after the interim analysis. All IRC-related efficacy analyses in this clinical study report were based on the interim analysis data cutoff date of 15 January 2019. All other efficacy analyses were based on the final analysis data cutoff date of 03 September 2021.
Time frame: IRC assessments from randomization date until disease progression or death or IRC discontinuation on 15Jan2019 (as IA per this data cutoff showed crossing superiority boundary) whichever came first, up to 22 months of follow-up
Population: Intent-to-treat population including all randomized participants
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Acalabrutinib Monotherapy | Progression-free Survival (PFS) Per Independent Review Committee (IRC) Assessment | NA Months |
| Arm B: Investigators Choice | Progression-free Survival (PFS) Per Independent Review Committee (IRC) Assessment | 16.5 Months |
p-value: <0.000195% CI: [0.2, 0.49]Log Rank
Secondary
Duration of Response (DOR) Per Independent Review Committee (IRC) Assessment Based on 15 January 2019 Data Cutoff From Interim Analysis.
Duration of Response (DOR) is defined as from the first documentation of CR, CRi, PR, or nPR to the earlier of the first documentation of disease progression or death from any cause.
Time frame: IRC assessments from randomization date until disease progression or death or IRC discontinuation on 15Jan2019 (as IA per this data cutoff showed crossing superiority boundary) whichever came first, up to 22 months of follow-up
Population: Intent to treat (ITT) population including all randomized participants
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Acalabrutinib Monotherapy | Duration of Response (DOR) Per Independent Review Committee (IRC) Assessment Based on 15 January 2019 Data Cutoff From Interim Analysis. | NA Months |
| Arm B: Investigators Choice | Duration of Response (DOR) Per Independent Review Committee (IRC) Assessment Based on 15 January 2019 Data Cutoff From Interim Analysis. | 13.6 Months |
p-value: <0.000195% CI: [0.19, 0.59]Log Rank
Secondary
Duration of Response (DOR) Per Investigator Assessment Based on 03 September 2021 Data Cutoff
Duration of Response (DOR) is defined as from the first documentation of CR, CRi, PR, or nPR to the earlier of the first documentation of disease progression or death from any cause.
Time frame: Investigator assessments were done from randomization date until date of death or study discontinuation or data cutoff date on 03Sep2021, whichever came first up to 53 months of follow-up.
Population: Intent to treat (ITT) population including all randomized participants
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Acalabrutinib Monotherapy | Duration of Response (DOR) Per Investigator Assessment Based on 03 September 2021 Data Cutoff | NA Months |
| Arm B: Investigators Choice | Duration of Response (DOR) Per Investigator Assessment Based on 03 September 2021 Data Cutoff | 18.3 Months |
p-value: <0.000195% CI: [0.16, 0.33]Log Rank
Secondary
Investigator Assessed Overall Response Rate (ORR) Per IWCLL 2008 Criteria Based on Data Cutoff 03 September 2021
IRC-assessed overall response rate (ORR) including complete response (CR), CR with incomplete blood count recovery (CRi) nodular PR (nPR), and Partial Response (PR)
Time frame: Investigator assessments were done from randomization date until date of death or date of exit from study or data cut off date on 03Sep2021, whichever came first, up to 53 months of follow-up.
Population: Intent-to-treat population including all randomized participants
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm A: Acalabrutinib Monotherapy | Investigator Assessed Overall Response Rate (ORR) Per IWCLL 2008 Criteria Based on Data Cutoff 03 September 2021 | 128 Participants |
| Arm B: Investigators Choice | Investigator Assessed Overall Response Rate (ORR) Per IWCLL 2008 Criteria Based on Data Cutoff 03 September 2021 | 130 Participants |
p-value: 0.73495% CI: [-9.6, 7]Cochran-Mantel-Haenszel
Secondary
IRC-assessed Overall Response Rate (ORR) Per IWCLL 2008 Criteria Based on Data Cutoff 15 January 2019 From Interim Analysis
IRC-assessed overall response rate (ORR) including complete response (CR), CR with incomplete blood count recovery (CRi) nodular PR (nPR), and Partial Response (PR)
Time frame: IRC assessments from randomization date until disease progression or death or IRC discontinuation on 15Jan2019 (as IA per this data cutoff showed crossing superiority boundary) whichever came first, up to 22 months of follow-up
Population: Intent-to-treat population including all randomized participants
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm A: Acalabrutinib Monotherapy | IRC-assessed Overall Response Rate (ORR) Per IWCLL 2008 Criteria Based on Data Cutoff 15 January 2019 From Interim Analysis | 126 Participants |
| Arm B: Investigators Choice | IRC-assessed Overall Response Rate (ORR) Per IWCLL 2008 Criteria Based on Data Cutoff 15 January 2019 From Interim Analysis | 117 Participants |
p-value: 0.224895% CI: [-3.3, 14.9]Cochran-Mantel-Haenszel
Secondary
Overall Survival (OS)
Overall Survival (OS) was based on data cutoff date of 03Sep2021
Time frame: From randomization date to date of death due to any cause, or date of study discontinuation, or date of data cutoff on 03Sep2021, whichever came first until 54 months of follow-up.
Population: Intent-to treat (ITT) population including all randomized participants
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Acalabrutinib Monotherapy | Overall Survival (OS) | NA Months |
| Arm B: Investigators Choice | Overall Survival (OS) | NA Months |
Comparison: Analysis stratified by factors recorded in IXRS data including presence of deletion 17 p (yes / no), ECOG (0-1/2), # of prior therapies (1-3/4+).p-value: 0.078395% CI: [0.46, 1.04]Log Rank
Secondary
Progression-free Survival (PFS) Per Investigator Assessment
PFS per investigator assessment based on the final analysis data cutoff date of 03 September 2021.
Time frame: From randomization date to date of disease progression or death due to any cause or data cutoff date on 03Sep2021, whichever came first, regardless of use of subsequent anticancer therapy, until 53 months of follow-up.
Population: Intent-to-treat population including all randomized participants
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Acalabrutinib Monotherapy | Progression-free Survival (PFS) Per Investigator Assessment | NA Months |
| Arm B: Investigators Choice | Progression-free Survival (PFS) Per Investigator Assessment | 16.8 Months |
p-value: <0.000195% CI: [0.2, 0.38]Log Rank
Secondary
Time to Next Treatment (TTNT) Based on 03 September 2021 Data Cutoff
Time to Next Treatment (TTNT) is defined as the time from date of randomization to date of institution of non-protocol-specified treatment for CLL (or first dose date of acalabrutinib for Arm B subjects crossing over to receive acalabrutinib) or death due to any cause, whichever comes first.
Time frame: From randomization date to start of non-protocol specified subsequent anticancer therapy for CLL or death due to any cause or study discontinuation or data cutoff date on 03Sep2021,, whichever came first up to 53 months of follow-up.
Population: Intent to treat (ITT) population including all randomized participants
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Acalabrutinib Monotherapy | Time to Next Treatment (TTNT) Based on 03 September 2021 Data Cutoff | NA Months |
| Arm B: Investigators Choice | Time to Next Treatment (TTNT) Based on 03 September 2021 Data Cutoff | 22.5 Months |
p-value: <0.000195% CI: [0.21, 0.4]Log Rank